Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer

International Journal of Gynecological Pathology

Volumn 29, Issue 1, 2010, Pages 8-18

  Duncan, Timothy J ^a   Al Attar, Ahmad ^a   Rolland, Phil ^a   Harper, Sarah ^a   Spendlove, Ian ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Ovarian cancer; P27; Prognostic marker

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ADULT; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL MOTILITY; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 76149093205     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181b64ec3     Document Type: Article

References (52)

1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512
2. Lacy ER, Filippov I, Lewis WS, et al. p27 binds cyclin-CDK complexes through a sequential mechanism involving bindinginduced protein folding. Nat Struct Mol Biol 2004;11:358-364
3. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685
4. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-323
5. Loda M, Cukor B, Tam SW, et al. Increased proteasomedependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234
6. Masciullo V, Sgambato A, Pacilio C, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999;59:3790-3794
7. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259-1263
8. Rahman A, Maitra A, Ashfaq R, et al. Loss of p27 nuclear expression in a prognostically favorable subset of welldifferentiated pancreatic endocrine neoplasms. Am J Clin Pathol 2003;120:685-690
9. Watanabe J, Sato H, Kanai T, et al. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus-correlation with proliferation and clinicopathological parameters. Br J Cancer 2002;87:81-85
10. Korkolopoulou P, Vassilopoulos I, Konstantinidou AE, et al. The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 2002;85:404-414
11. Psyrri A, Bamias A, Yu Z, et al. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 2005;11:8384-8390
12. Schmider-Ross A, Pirsig O, Gottschalk E, et al. Cyclindependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. J Cancer Res Clin Oncol 2006;132:163-170
13. Masciullo V, Ferrandina G, Pucci B, et al. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 2000;6: 4816-4822
14. O'Toole SA, Sheppard BL, Laios A, et al. Potential predictors of chemotherapy response in ovarian cancer: how do we define chemosensitivity? Gynecol Oncol 2007;104:345-351
15. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-6385
16. Duncan TJ, Rolland P, Deen S, et al. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007;13:4139-4145
17. Rosen DG, Yang G, Cai KQ, et al. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 2005;11(2 Pt 1):632-637
18. Bland JM, Altman DG. Measurement error and correlation coefficients. BMJ 1996;313:41-42.
19. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-230
20. Mori M, Mimori K, Shiraishi T, et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593.
21. Korkolopoulou P, Christodoulou P, Konstantinidou AE, et al. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 2000;31:751-760
22. Baekelandt M, Holm R, Trope CG, et al. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res 1999;5:2848-2853 (Pubitemid 29493962)
23. Newcomb EW, Sosnow M, Demopoulos RI, et al. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 1999;154:119-125
24. Shimizu M, Nikaido T, Toki T, et al. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999;85:669-677
25. Sui L, Dong Y, Ohno M, et al. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001;83:56-63. (Pubitemid 32959879)
26. Berek J. Epithelial ovarian cancer. In: Berek JH, Hacker NF, eds. Practical Gynecological Oncology. 4th ed. Philadephia, PA: Lippincott Williams & Wilkins; 2005.
27. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003;21:3488-3494
28. Schneider J, Pollan M, Jimenez E, et al. nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. Br J Cancer 2000;82:1662-1670
29. Ciaparrone M, Yamamoto H, Yao Y, et al. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 1998;58:114-122
30. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-3385
31. Zhang H, Sun XF. Loss of p27 expression predicts poor prognosis in patients with Dukes' B stage or proximal colorectal cancer. Int J Oncol 2001;19:49-52.
32. Sgambato A, Ratto C, Faraglia B, et al. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog 1999;26:172-179
33. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-1144
34. ChengM, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J 1999;18:1571-1583
35. Eymin B, Haugg M, Droin N, et al. p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 1999;18:1411-1418
36. Woltman AM, van der Kooij SW, Coffer PJ, et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003;101:1439-1445
37. Besson A, Gurian-West M, Schmidt A, et al. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004;18:862-876
38. Watson NF, Durrant LG, Scholefield JH, et al. Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients. World J Gastroenterol 2006;12:6299-6304
39. Nycum LR, Smith LM, Farley JH, et al. The role of p27 in endometrial carcinoma. Gynecol Oncol 2001;81:242-246
40. Kouvaraki M, Gorgoulis VG, Rassidakis GZ, et al. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors. Cancer 2002;94:2454-2465
41. Hurteau JA, Allison BM, Brutkiewicz SA, et al. Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer. Gynecol Oncol 2001;83:292-298
42. Shigemasa K, Shiroyama Y, Sawasaki T, et al. Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. Int J Oncol 2001;18:953-958
43. Cheng JD, Werness BA, Babb JS, et al. Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin Cancer Res 1999;5:1057-1062
44. Shoji M, Dobashi Y, Morinaga S, et al. Tumor extension and cell proliferation in adenocarcinomas of the lung. Am J Pathol 1999;154:909-918
45. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002;8:1076-1078
46. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in nonneoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996; 180:122-128
47. Sanchez-Beato M, Saez AI, Martinez-Montero JC, et al. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 1997;151:151-160
48. Balsitis S, Dick F, Dyson N, et al. Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res 2006;66:9393-9400
49. Cho NH, Kim YT, Kim JW. Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. Yonsei Med J 2002;43:722-728
50. Xing H, Wang S, Hu K, et al. Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. J Cancer Res Clin Oncol 2005;131:511-519
51. Martin C, Walker J, Rothnie A, et al. The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models. Br J Cancer 2003;89:1581-1589
52. Xing H, Wang S, Weng D, et al. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep 2007;17:117-122